USD 3.54 Billion
Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type(Nintedanib, Pirfenidone, Other Drug Types), By Mode of Action(Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By End User(Hospitals and Clinics, Pharmacies, Other End Users ), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35H2223 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|Tables:
61
|Figures:
75
Idiopathic Pulmonary Fibrosis Market Insights
Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.50 billion in 2022 and is poised to grow from USD 4.02 billion in 2023 to USD 10.80 billion by 2031, growing at a CAGR of 6.98% during the forecast period (2024-2031).
The increasing number of idiopathic pulmonary fibrosis patients is placing a growing requirement on the medical staff to formulate effective treatment measures. As IPF is disabling in nature, it is necessary to introduce management techniques that enhance the quality of life of the patients. In this regard, there arises an increased demand for novel therapeutic alternatives. This demographic transition has drawn out the need to upscale healthcare services and manage this condition that is increasingly arising and being difficult to deal with. The idiopathic pulmonary fibrosis market growth is significantly driven by attractive reimbursement policies by manufacturers and insurance companies in some countries and the increasing demand for the best drugs in treatment of idiopathic pulmonary fibrosis. The main growth drivers for the idiopathic pulmonary fibrosis market are the growth in the elderly population, the prevalence of fibrotic disease, and the technological advancements in cancer screening and detection. Additionally, the market is growing because of the availability of new treatment options and the increased demand for cheaper drugs. Pharmaceutical companies are investing in further clinical trials and new therapeutic methods to prove their further commitment to satisfying unmet medical needs in this respect. These advancements are said to expand the scope of treatment options by a significant measure, which would further direct the IPF treatment market toward significant growth. Moreover, the market growth will be limited by the insufficient treatment options for the disease.
US Idiopathic Pulmonary Fibrosis Market is poised to grow at a sustainable CAGR for the next forecast year.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Nintedanib
Fastest Growth
Nintedanib
Growth Rate
6.9% CAGR
Global Idiopathic Pulmonary Fibrosis Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Idiopathic Pulmonary Fibrosis Market Segmental Analysis
Global Idiopathic Pulmonary Fibrosis Market is segmented on the basis Global Idiopathic Pulmonary Fibrosis Market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Idiopathic Pulmonary Fibrosis Market Analysis by Drug Class
The pirfenidone segment dominated the market and accounted for 43.0% of the idiopathic pulmonary fibrosis market share in 2024. Regulatory authorities have approved pirfenidone as a standard treatment option due to its unique combination of anti-fibrotic, anti-inflammatory, and antioxidant properties. This multifaceted approach not only addresses the underlying mechanisms of idiopathic pulmonary fibrosis (IPF) but also enhances the quality of life for patients. The drug's proven efficacy in clinical trials, combined with ongoing research and development initiatives, significantly increases its value and attractiveness to healthcare providers and patients alike. As more healthcare professionals recognize the benefits of pirfenidone, its market share is predicted to remain strong, reinforcing its role as a cornerstone in IPF management.
The nintedanib segment is expected to grow at the fastest CAGR of 8.0% over the forecast period. Clinical trials, particularly the INPULSIS studies, have demonstrated that nintedanib significantly reduces the annual decline in forced vital capacity (FVC) by approximately 50% compared to placebo. This impressive outcome is particularly valuable for patients across various stages of the disease, providing hope for improved lung function and overall health. Furthermore, nintedanib boasts a favorable safety profile, with side effects primarily associated with gastrointestinal concerns, making it a compelling option for many patients. As awareness of its benefits grows, the demand for nintedanib is expected to rise, further solidifying its presence in the idiopathic pulmonary fibrosis industry.
Idiopathic Pulmonary Fibrosis Market Analysis by Route of Administration
The Oral segment led the idiopathic pulmonary fibrosis industry with a revenue share of 69.3% in 2024. These two oral drugs, pirfenidone and nintedanib, add greatly to patient compliance since they can be administered via the less invasive route of orally instead of injectables. Their mild administration profile, as well as established efficacy to slow disease progression and preserve lung function, makes both drugs very appealing to patients and providers. Safety profiles also help in mitigating potential concerns of adverse effects, thus opening doors to further adoption. As healthcare providers seek effective treatments that seamlessly complement the daily lives of patients, preference for oral medications is likely to fuel growth in this area of the market.
As per the idiopathic pulmonary fibrosis market analysis, the injectable segment is expected to register a steady growth rate over the forecast period. While oral therapies such as pirfenidone and nintedanib are popular, injectable medications offer distinct advantages for certain patient populations. These treatments are particularly beneficial to the patients who are highly non-adherent to oral drugs or have severe disease progression, allowing a more appropriate scheme that suits them. Emerging research in new injectable preparations and combination therapies is bringing better results with the assistance of overall treatments for IPF patients. Targeted dosing strategies are also being developed to ensure enhanced safety and to reduce the risk of side effects that make IPF manageable. This is because with the advancements that are made, injectable medicines are going to play a very important role and give their precious alternatives in patient care.
Global Idiopathic Pulmonary Fibrosis Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Idiopathic Pulmonary Fibrosis Market Regional Insights
As per the idiopathic pulmonary fibrosis market forecast, North America dominated the market with 37.5% revenues in 2024. Developed healthcare infrastructure, well-equipped hospitals, and specialist IPF diagnostic and management skills facilitate timely and efficient treatment in the region. In addition, access to authorized treatments such as pirfenidone and nintedanib is supplemented by strong R&D with favorable reimbursement policies. The U.S. market captured the largest share of the North America market for the treatment of idiopathic pulmonary fibrosis in 2024. The nation is well-supported by a developed health care system, which permits timely diagnosis and effective decision of the treatment. The fast approval of medicines pirfenidone and nintedanib improved access for patients, while continued research and development activities in the United States continue to foster innovative therapeutic approaches.
Asia-Pacific idiopathic pulmonary fibrosis industry is expected to grow at the highest CAGR of 7.8% during the period of the forecast. High awareness of the illness along with easier access to health care boosts the requirement for effective treatment options. In addition, advancement in diagnostic technology, pharmaceutical innovations, and good infrastructural and healthcare facilities enable the management of chronic diseases such as IPF through collaboration between pharmaceutical companies and research centers. The China idiopathic pulmonary fibrosis market size in 2024 accounted for a significant share in the Asia Pacific market. Improved healthcare access, increasing awareness about IPF, and a need for effective treatment options drive this demand. The continuous research work pushes patient-centric medicines and aids the Chinese government's interest in improving the healthcare infrastructure as well as the increase in insurance coverage of chronic diseases.
Global Idiopathic Pulmonary Fibrosis Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Idiopathic Pulmonary Fibrosis Market Dynamics
Idiopathic Pulmonary Fibrosis Market Drivers
Increasing Prevalence of IPF
- The prevalence of idiopathic pulmonary fibrosis is rising due to the growing age of the population and increasing environmental factors that include and more than which is air pollution and occupational exposures. Such increased awareness among patients and medical professionals also contributes to this increasing incidence that leads to increased diagnosis. The growing demand for advanced treatment and management options is an important factor driving the idiopathic pulmonary fibrosis market growth.
Research and Development Innovations
- Research into the etiology of IPF has made novel treatments such as immunomodulators and antifibrotics possible. Higher investment in clinical trials is creating dynamic treatment environments that do not only raise the possibility of better patient results but also pique investors' interest. This development gives patients new hope of a better quality of life and efficient management of IPF.
Idiopathic Pulmonary Fibrosis Restraints
High-Cost of Healthcare
- One of the prominent challenges to penetrating the idiopathic pulmonary fibrosis market outlook is the high prices of the available IPF drugs. Most patients forgo their prescription drugs due to their high cost of treatment. This results in a poor condition of disease management. This financial burden further strains healthcare systems. It is especially in low- and middle-income areas where access to essential treatments continues to become increasingly restricted and unequal.
Lack of Awareness and Recognition
- Idiopathic pulmonary fibrosis is increasingly becoming known, but due to its complexity and ambiguous symptoms, it remains an underdiagnosed disease. Most individuals may fail to realize the subtle early signs of the disease, causing delays in vital medical care until such a stage where it is too late. It resulted in ignorance, which puts back treatment at the right time and limits market growth while eventually leading to poor health for patients with IPF.
Request Free Customization of this report to help us to meet your business objectives.
Idiopathic Pulmonary Fibrosis Market Competitive Landscape
The competitive landscape of the global idiopathic pulmonary fibrosis (IPF) industry is characterized by intensive research and development work on developing new treatment modalities and improving patient outcomes. Pharmaceutical companies are aggressively launching targeted treatments and antifibrotic medicines to fulfill the unmet medical needs of IPF patients. Patient organizations and advocacy groups are also assisting in raising awareness about IPF and its treatment; however, healthcare professionals and research institutions play a critical role in improving patient care and diagnostic approaches.
Idiopathic Pulmonary Fibrosis Market Top Player’s Company Profiles
- United Therapeutics Corporation
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche Ltd
- FibroGen Inc.
- MediciNova Inc.
- Jubilant Pharma Limited (Jubilant Cadista Limited)
- Merck & Co. Inc.
- Horizon Therapeutics Inc.
- Avalyn Pharma Inc.
- AstraZeneca
- Novartis AG
- GlaxoSmithKline plc
- Genentech, Inc.
- Biogen Inc.
- Pfizer Inc.
- AbbVie Inc.
- Bayer AG
- Amgen Inc.
Idiopathic Pulmonary Fibrosis Market Recent Developments
- Plans to file a new drug application for the treatment of IPF were prompted by an announcement that Boehringer Ingelheim issued on September 2024 stating that nerandomilast FIBRONEER-IPF trial achieved its primary objective.
- Options for Indications of Idiopathic and Progressive Pulmonary Fibrosis, Ferrer extended the exclusive licensing agreement in May 2024 with United Therapeutics to acquire worldwide rights of treprostinil inhalation solution.
- Daewoong Pharmaceutical and CS Pharmaceuticals agreed on the license for the first-in-class PRS inhibitor Bersiporocin to be distributed in Greater China in January 2023. It involves mainland China, Hong Kong, Taiwan, and Macau. For the aggregate amount up to USD 336m consisting of the sum of up to USD 76m in milestone payments due upon the achievement of specified development milestones, plus double-digit royalties on net sales, CSP shall license in bersiporocin for IPF and for other fibrotic conditions.
Idiopathic Pulmonary Fibrosis Key Market Trends
- Trend of Personalized Medication: One of the major idiopathic pulmonary fibrosis market trends includes personalization of medicines. Personalized medication in idiopathic pulmonary fibrosis IPF is growing rapidly in the market. Advances in the genetics field and discovery of biomarkers have made possible individualized treatment plans, introduced by healthcare experts for the first time. Tailor-made medicines for the characteristics of each patient will continue to increase the effectiveness of therapy, which will bring improvements in disease management as well as treatment and overall outcomes for patients.
- Digital Health Innovations: Integration of digital health technology, particularly telemedicine platforms and mobile health applications, is revolutionizing IPF treatment. These features improve interaction and enhance remote patient monitoring, which can result in better access to health care. Other than an aid for research, technologies like these can empower patients toward more active involvement in the care process through improved program adherence and acquisition of potential data.
Idiopathic Pulmonary Fibrosis Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the idiopathic pulmonary fibrosis industry is expected to grow significantly since the incidence rates are rising, and R&D in this area is advancing. Advances in digital health and personalized medicine are reshaping treatment paradigms and providing individualized strategies for improving patient outcomes. These issues need to be overcome to tap the full potential of the market. Stakes can build a more supportive environment for the patient by sensitizing and making easier access to effective treatments. As more people will be expected to be placed on effective treatment the obstacles will have to be crossed by keeping the continuous flow of funds research, technology, and education as the environment changes.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 3.50 billion |
| Market size value in 2031 | USD 10.80 billion |
| Growth Rate | 6.98% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Idiopathic Pulmonary Fibrosis Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Idiopathic Pulmonary Fibrosis Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Idiopathic Pulmonary Fibrosis Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Idiopathic Pulmonary Fibrosis Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Idiopathic Pulmonary Fibrosis Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Idiopathic Pulmonary Fibrosis Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
